Two Distinct Motifs within the p53 Transactivation Domain Bind to the Taz2 Domain of p300 and Are Differentially Affected by Phosphorylation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The tumor suppressor p53 functions as a transcriptional activator for many genes, including several key genes involved in cell cycle arrest and apoptosis. Following DNA damage-induced stress, p53 undergoes extensive posttranslational modification, resulting in increased stability and activity. Two critical cofactors for p53-mediated transactivation are the histone acetyltransferase paralogues CREB-binding protein (CBP) and p300. The N-terminal transactivation domain of p53 interacts with several domains of CBP/p300, including the Taz2 domain. Here, we report the effects of specific p53 phosphorylations on its interaction with the Taz2 domain of p300. Using a competitive fluorescence anisotropy assay, we determined that monophosphorylation of p53 at Ser(15) or Thr(18) increased the affinity of p53(1-39) for Taz2, and diphosphorylations at Ser(15) and Ser(37) or Thr(18) and Ser(20) further increased the affinity. In addition, we identified a second binding site for Taz2 within p53 residues 35-59. This second site bound Taz2 with a similar affinity as the first site, but the binding was unaffected by phosphorylation. Thus, p53 posttranslational modification modulates only one of the two binding sites for p300 Taz2. Further investigation of Taz2 binding to p53(1-39) or p53(35-59) by isothermal titration calorimetry indicated that upon complex formation, the change in heat capacity at constant pressure, DeltaC(p), was negative for both sites, suggesting the importance of hydrophobic interactions. However, the more negative value of DeltaC(p) for Taz2 binding to the first (-330 cal/(mol.K)) compared to the second site (-234 cal/(mol.K)) suggests that the importance of nonpolar and polar interactions differs between the two sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 9×
“examined the binding of the p53 TAD to the Taz1, KIX, Taz2, and IBiD domains of p300, finding that p53(1-57) binds to each of the four domains with moderate to high affinity (30).”
BackgroundMethodInfluentialCBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778 · cited 10×
“examined the binding of the p53 TAD to the Taz1, KIX, Taz2, and IBiD domains of p300, finding that p53(1-57) binds to each of the four domains with moderate to high affinity (30).”
BackgroundMethodInfluentialDNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204 · cited 10×
“examined the binding of the p53 TAD to the Taz1, KIX, Taz2, and IBiD domains of p300, finding that p53(1-57) binds to each of the four domains with moderate to high affinity (30).”
BackgroundMethodSelf-citationBarlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710 · cited 10×
“examined the binding of the p53 TAD to the Taz1, KIX, Taz2, and IBiD domains of p300, finding that p53(1-57) binds to each of the four domains with moderate to high affinity (30).”
BackgroundMethodInfluentialDumaz, N., & Meek, D. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.24.7002 · Cited by 455
p300/MDM2 complexes participate in MDM2-mediated p53 degradation
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414 · cited 10×
“examined the binding of the p53 TAD to the Taz1, KIX, Taz2, and IBiD domains of p300, finding that p53(1-57) binds to each of the four domains with moderate to high affinity (30).”
BackgroundMethodInfluentialParker, D., Ferreri, K., Nakajima, T., Lamorte, V. J., Evans, R., Koerber, S. C., Hoeger, C., & Montminy, M. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.2.694 · Cited by 408
Comparative study of the p53-mdm2 and p53-MDMX interfaces
Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · cited 10×
“examined the binding of the p53 TAD to the Taz1, KIX, Taz2, and IBiD domains of p300, finding that p53(1-57) binds to each of the four domains with moderate to high affinity (30).”
BackgroundMethodInfluential
Cited by
Tumour suppression by p53: a role for the DNA damage response?
Meek, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2716 · Cited by 609
Posttranslational Modification of p53: Cooperative Integrators of Function
Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 483
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
The Tumor Suppressor p53: From Structures to Drug Discovery
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 357
p53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
Wang, F., Marshall, C. B., & Ikura, M. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1254-4 · Cited by 309
Loughery, J., Cox, M., Smith, L. M., & Meek, D. W. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku501 · Cited by 305
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Deciphering the acetylation code of p53 in transcription regulation and tumor suppression
Xia, Z., Kon, N., Gu, A. P., Tavana, O., & Gu, W. (2022) · Oncogene · doi:10.1038/s41388-022-02331-9 · Cited by 60
The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
Kannan, S., Partridge, A. W., Lane, D. P., & Verma, C. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235996 · Cited by 17
Metadata
- Authors
- Jenkins, L. M. M., Yamaguchi, H., Hayashi, R., Cherry, S., Tropea, J. E., Miller, M., Wlodawer, A., Appella, E., & Mazur, S. J.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-01-23
- Volume
- 48
- Issue
- 6
- Pages
- 1244-1255
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2109047894
- Cited by
- 63
- References
- 8
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.